Document text
Principal Investigator: JOHN S. LAZO
Organization: KEVIRX INC.
Fiscal Year: 2022
Award: $55,000
Funding agency: National Heart Lung and Blood Institute
The Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) is responsible for the current
COVID-19 pandemic. SAR-CoV-2, like other coronaviruses, infects human airways and enters cells via its S
(Spike) protein, which binds to the human angiotensin-converting enzyme 2 (ACE2) and is primed by the host
serine protease TMPRSS2. Both ACE2 and TMPRSS2 have been observed on pulmonary microvascular
epithelium and endothelium. A subset of COVID-19 patients develop acute respiratory distress syndrome
(ARDS) and subsequently septic shock and multi-organ failure; about half will die. The clinical worsening in the
later phases of COVID-19 are thought to result from Spike protein binding to the pulmonary microvascular
endothelium and epithelium, which leads to a damaged respiratory tract and ultimately a systemic inflammatory
response or cytokine storm. There are currently no FDA-approved drugs/therapeutics that treat the pulmonary
damage and ARDS associated with COVID-19. KeViRx is proposing to develop an entirely new therapeutic
strategy that prevents or mitigates the initial pulmonary damage and halts the lethal cytokine storm.
Our lead compound, KVX-053, is a reversible, selective, allosteric inhibitor of PTP4A3 phosphatase with
excellent in vivo pharmacokinetic properties and drug-like properties. Moreover, mice tolerated multiple
exposures to KVX-053. In culture KVX-053 was not cytotoxic to human ovarian epithelial cells or fibroblasts at
concentrations up to 25 µM. Surprisingly, we found that KVX-053 markedly enhanced the pulmonary
microvascular barrier function before and after injury caused by bacterial lipopolysaccharide and vascular
endothelial growth factor. PTP4A3 phosphatase is known to be induced in lung cells 12 h after SARS-CoV
infection and to control cytokine release. The overall hypothesis of this Phase I SBIR application is that the
PTP4A phosphatase family has a sentinel role in the acute lung injury of ARDS and the systemic inflammatory
response in COVID-19.The overall goal of the project is to repurpose KVX-053 for use against SARS-CoV-2
infection and for future viral pandemics involving acute lung injury. This Phase I SBIR application has three proof-
of-concept Specific Tasks. Specific Task 1 will determine the ability of a novel, potent, allosteric, small molecule
PTP4A inhibitor, KVX-053, to block SARS-CoV-2 Spike 1 protein-mediated loss of pulmonary endothelial barrier
function and cytokine release in vitro. Specific Task 2 will determine the ability of KVX-053 to block SARS-CoV-
2 Spike 1 protein-mediated pulmonary alveolar epithelial barrier function and cytokine release in vitro. Specific
Task 3 will determine the ability of KVX-053 to inhibit acute lung injury in mice caused by the SARS-CoV-2 Spike
1 protein.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><ACE2><ARDS><Acute Lung Injury><Acute Pulmonary Injury><Acute Respiratory Distress><Acute Respiratory Distress Syndrome><Adult ARDS><Adult RDS><Adult Respiratory Distress Syndrome><Binding><Binding Proteins><COVID crisis><COVID epidemic><COVID infected patient><COVID pandemic><COVID patient><COVID positive patient><COVID-19><COVID-19 crisis><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 infected patient><COVID-19 infection><COVID-19 pandemic><COVID-19 patient><COVID-19 positive patient><COVID-19 public health crisis><COVID-19 virus><COVID19><COVID19 crisis><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 infection><COVID19 pandemic><COVID19 patient><COVID19 positive patient><COVID19 public health crisis><COVID19 virus><CV-19><CV19><Cell Body><Cells><Clinical><CoV-2><CoV2><Coronaviridae><Coronavirus><Da Nang Lung><Drug Kinetics><Drugs><Endothelium><Epithelial><Epithelial Cells><Epitheliasin Gene><Exposure to><FDA approved><Family><Fibroblasts><Future><Goals><HH13><HH7-2><HH72><Human><In Vitro><Individual><Infection><Injury><Lead><Ligand Binding Protein><Ligand Binding Protein Gene><Lipopolysaccharides><Lung><Lung Alveolar Epithelia><Lung Respiratory System><Lung damage><MOF syndrome><Mediating><Medication><Mice><Mice Mammals><Modern Man><Molecular Interaction><Multiple Organ Dysfunction Syndrome><Multiple Organ Failure><Murine><Mus><OV1><Ovarian><PRL2><PRSS10><PTP(CAAX2)><PTP4A><PTP4A1><PTP4A2 gene><Pb element><Pharmaceutic Preparations><Pharmaceutical Preparations><Pharmacokinetics><Phase><Phosphatase of Regenerating Liver 2><Phosphatases><Phosphohydrolases><Phosphomonoesterases><Phosphoric Monoester Hydrolases><Property><Protein Binding><Protein-Tyrosine Phosphatase, Type 4A, 2><Proteins><Pulmonary Body System><Pulmonary Organ System><Respiratory System><Respiratory Tracts><Respiratory tract structure><Role><SARS Virus><SARS corona virus><SARS corona virus 2><SARS coronavirus><SARS-Associated Coronavirus><SARS-CO-V2><SARS-COVID-2><SARS-CoV><SARS-CoV-1><SARS-CoV-2><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 infected patient><SARS-CoV-2 infection><SARS-CoV-2 inhibitor><SARS-CoV-2 pandemic><SARS-CoV-2 patient><SARS-CoV-2 positive patient><SARS-CoV2><SARS-CoV2 epidemic><SARS-CoV2 infection><SARS-CoV2 pandemic><SARS-Related Coronavirus><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><SBIR><Sentinel><Septic Shock><Serine Endopeptidases><Serine Protease><Serine Protein Hydrolases><Serine Proteinases><Severe Acute Respiratory Coronavirus><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome Virus><Severe Acute Respiratory Syndrome corona virus><Severe Acute Respiratory Syndrome coronavirus><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 inhibitor><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome related corona virus 2><Shock Lung><Small Business Innovation Research><Small Business Innovation Research Grant><Stiff lung><TMPRSS2><TMPRSS2 gene><Therapeutic><VEGF><VEGFs><Vascular Endothelial Growth Factors><Viral><Wuhan coronavirus><alveolar epithelium><angiotensin converting enzyme 2><angiotensin converting enzyme II><block SARS-CoV-2><block severe acute respiratory syndrome coronavirus 2><bound protein><corona virus><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><coronavirus disease 2019><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 infected patient><coronavirus disease 2019 infection><coronavirus disease 2019 pandemic><coronavirus disease 2019 patient><coronavirus disease 2019 positive patient><coronavirus disease 2019 public health crisis><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease infected patient><coronavirus disease pandemic><coronavirus disease patient><coronavirus disease positive patient><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 pandemic><coronavirus disease-19 patient><coronavirus disease-19 virus><coronavirus infectious disease-19><coronavirus patient><cytokine><cytokine release syndrome><cytokine storm><drug/agent><hCoV19><heavy metal Pb><heavy metal lead><in vivo><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><inhibit SARS-CoV-2><inhibit severe acute respiratory syndrome coronavirus 2><inhibitor><injuries><lung injury><multiorgan failure><multiple organ system failure><nCoV2><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapy approaches><novel><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapy approach><pandemic><pandemic disease><patient infected with COVID><patient infected with COVID-19><patient infected with SARS-CoV-2><patient infected with coronavirus disease><patient infected with coronavirus disease 2019><patient infected with severe acute respiratory syndrome coronavirus 2><patient with COVID><patient with COVID-19><patient with COVID19><patient with SARS-CoV-2><patient with coronavirus disease><patient with coronavirus disease 2019><patient with severe acute respiratory distress syndrome coronavirus 2><prevent><preventing><pulmonary><pulmonary damage><pulmonary injury><pulmonary tissue damage><pulmonary tissue injury><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 infected patient><severe acute respiratory syndrome coronavirus 2 patient><severe acute respiratory syndrome coronavirus 2 positive patient><severe acute respiratory syndrome-CoV><small molecule><social role><systemic inflammation><systemic inflammatory response><wet lung>